Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Trial Identifier: D7680C00001
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: June 2025
Study Completion Date: June 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
USA, California Los Angeles, California, USA, 90027
USA, California Los Angeles, California, USA, 90033
USA, Colorado Denver, Colorado, USA, 80204
USA, Colorado Golden, Colorado, USA, 80222
USA, Florida Miami Lakes, Florida, USA, 33014
USA, Illinois Skokie, Illinois, USA, 60076
USA, Iowa Ames, Iowa, USA, 50010-3014
USA, Louisiana Covington, Louisiana, USA, 70433
USA, Michigan Troy, Michigan, USA, 48098
USA, New Jersey Florham Park, New Jersey, USA, 07932
USA, New Jersey Mickleton, New Jersey, USA, 08056
USA, New York Shirley, New York, USA, 11967
USA, New York Westbury, New York, USA, 11590
USA, Ohio Canton, Ohio, USA, 44710
USA, Ohio Canton, Ohio, USA, 44708
USA, Ohio Cincinnati, Ohio, USA, 45219
USA, Ohio Massillon, Ohio, USA, 44646
USA, Pennsylvania York, Pennsylvania, USA, 17403
USA, Texas Austin, Texas, USA, 78745
USA, Texas Dallas, Texas, USA, 75246
USA, Texas Houston, Texas, USA, 77024
USA, Texas Longview, Texas, USA, 75601
USA, Texas Odessa, Texas, USA, 79902